| Dermatitis |
1 |
1 |
| Atopic Dermatitis |
0 |
1 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.5 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.44 |
| HIV Infection |
0 |
0.44 |
| Thromboembolism |
0 |
0.38 |
| Otolaryngology |
0 |
0.29 |
| Clinical Research |
0 |
0.25 |
| Topical Therapy |
0 |
0.25 |
| Brachial |
0 |
0.17 |
| Food and Drug Administration (FDA) |
0 |
0.17 |
| Steroids |
0 |
0.17 |
| Upper Respiratory Tract Infection |
0 |
0.12 |
| Adverse Effects |
0 |
0.08 |
| Board Certification |
0 |
0.08 |
| Bronchitis |
0 |
0.08 |
| Ear |
0 |
0.08 |
| Eosinophils |
0 |
0.08 |
| Europe |
0 |
0.08 |
| Folliculitis |
0 |
0.08 |
| Grant |
0 |
0.08 |
| Oregon |
0 |
0.08 |
| Pruritus |
0 |
0.08 |
| Respiratory Tract |
0 |
0.08 |
| Rhinorrhea |
0 |
0.08 |
| Thrombosis |
0 |
0.08 |
| Tonsillitis |
0 |
0.08 |
| Urticaria |
0 |
0.08 |
| Chronic Obstructive Pulmonary Disease |
0 |
0.07 |
| Diarrhea |
0 |
0.07 |
| Patient Safety |
0 |
0.07 |
| Skin and Soft Tissue Infection |
0 |
0.07 |
| Urticaria and Angioedema |
0 |
0.07 |